Currently, the risks and benefits of genomic sequencing for newborns are not well understood. All newborns receive a state-mandated heel stick blood test shortly after birth in order to screen for approximately 30 heritable, treatable conditions such as blood, endocrine, and metabolic disorders. Genomic sequencing has the potential to allow for significantly more extensive screening of … Continued
G2P’s summer began with our team members participating in the Boston Athletic Association 10K on Sunday June 23rd! Over the past few months, G2P faculty have attended numerous conferences nationwide, been featured in podcasts discussing the new preventive genomics clinic, and engaged with leaders in science, business, and industry in support of the Franca Fund.
When a newborn’s genome is sequenced, should some results be withheld?
Pediatric oncologist Dr. Lisa Diller, the Lillian Gollay Knafel Fellow at the Radcliffe Institute for Advanced Study, is exploring genetic testing in newborns that could help them escape severe health consequences.
Spring saw accomplishments by team members through numerous projects. G2P officially kicked-off the PeopleSeq consortium in Boston this January! Our very own, Carrie Blout, MS, CGC, was one of 86 Partner’s individuals awarded the Partners In Excellence Award.
Parents and clinicians have their own ideas about newborn genome sequencing. Dr. Robert Green, principal investigator of the BabySeq Project, shares a detailed analysis of the results from the study and his thoughts on the utility of genomic sequencing for newborns in clinical care.
Researchers analyzed nearly 5,000 genes looking for the risk of diseases and found that almost 10 percent of babies tested were at risk for a condition that could be treated early.
As principal investigator on the BabySeq Project, Dr. Robert Green shares the findings from the project along with discussion on the expectations and benefits of sequencing healthy babies. Green states, “Suddenly the information available in the genome of even an apparently healthy individual is looking more robust, and the prospect of preventive genomics is looking … Continued
In the BabySeq Study, a total of 88% of sequenced neonates had carrier status for one or more rare genetic variants known to be associated with recessive diseases.
Getting out in front of disease is the ultimate goal of DNA screening like the BabySeq project, says Dr. Robert Green, its joint director and a Harvard Medical School professor.
A trial called BabySeq, in which researchers performed genomic sequencing on 159 newborns, identified children susceptible to diseases that regular screening doesn’t look for.
Newborn DNA testing offers several potential benefits. Mainly, it could expand the number of conditions clinicians can test for before a child starts showing symptoms, giving them and patients a head start in handling the diseases.
Scientists were stunned by the number of babies with unanticipated genetic findings that could lead to disease prevention in the future.
Press Brief: The BabySeq project reports that out of the 159 newborns that were randomized to receive genomic sequencing, 15 were found to have a genetic variant for which there was a strong evidence of increased risk of a disorder that presents or is clinically manageable during childhood.
Robert Green, MD, MPH, the projects’ principal investigator suggests “These results are unexpected and exciting, suggesting that if we examine enough well-established, disease-associated genes, we will unearth monogenic risk variants in more than 10 percent of purportedly healthy individuals.”
This Fall, G2P has had exciting updates with a new PeopleSeq grant. Our team has traveled from San Diego, Atlanta, and Fort Detrick to Basel, Zurich, and Barcelona, to several conferences, presenting new data from our translational genomics research projects.
More information on newborn and adult sequencing studies unveiled at the 2018 American Society for Human Genetics Meeting in San Diego, CA. Two projects in which healthy individuals have had their genomes sequenced have revealed that searching for unanticipated genetic results in newborns and adults can unearth far more variants associated with diseases than previously thought, … Continued
“Sequencing at birth could provide a template—a book of life, if you will —to predict conditions or decide what medications to use for an entire lifetime,” says Robert Green, a medical geneticist at Brigham and Women’s and professor at Harvard Medical School who is co-leading the study.
Only about 7 percent of families approached to take part in the BabySeq Project of Brigham Women’s Hospital and Boston Children’s Hospital eventually enrolled, with many citing a lack of interest in research, study logistics, and privacy concerns as reasons for declining to participate.
Listen to WBUR’s radio segment on the BabySeq Project and one of its publications.
Press Brief: The BabySeq Project reports that although more than 80 percent of approached mothers and fathers declined an offer for free genomic sequencing of their newborn, more than half of those parents were not interested in any research participation.
Casie Genetti, MS, CGC, a licensed genetic counselor with the Manton Center for Orphan Disease Research at Boston Children’s Hospital is first author of a recently published paper on the BabySeq Project and author of this blog about parents’ receptiveness to genome sequencing.
Dr. Robert C. Green speaks at the 2018 Advances in Genome Biology and Technology (AGBT) Precision Health Conference in San Diego, California about our efforts to gather empirical data on genome sequencing healthy individuals. Watch to learn more about G2P’s MilSeq, BabySeq, MedSeq, PeopleSeq, PGen and REVEAL projects. Click here for more on the conference.
“According to Green, the Hastings report tries to take a broad view and is well done and well resourced. But he questioned whether recommendations of this type may be premature, considering that the research arms of NSIGHT are still early in the process of collecting, analyzing, and reporting their data.”
The third and final interview conducted with Dr. Robert Green about specific circumstances that could arise from genetic sequencing starting from infancy.
Follow new parents Katherine and Jason as they meet with Genomes2People Genetic Counselors to learn about their baby boy’s genome sequencing results as part of our BabySeq Project.
Dr. Robert C. Green talks about The BabySeq Project, the world’s first study of genetically sequencing newborns, and how genetic information can influence one’s medical care beginning from birth.
Genomic testing for Baby Cora, a participant of The BabySeq Project, revealed a disorder that might otherwise have gone undetected until life-long health issues presented themselves.
Highlights include a CBS feature on the BabySeq Project, the announcement of the MilSeq collaboration with the U.S. Air Force, and more.
Everyone talks about generating the clinical utility data necessary to integrate genomics into healthcare, but no one has taken this to heart more, or generated more of it, than Dr. Robert Green.
The idea of finding a risk in their beautiful baby of something that might or might not happen is terrifying or repugnant,” he says. “But other types of people are information seekers.”
Dr. Robert Green discusses genetic privacy concerns and questions about whole genome sequencing that have arisen from parents whose children are participating in the BabySeq project.
“Les parents, grands curieux, seraient même fous des données génomiques!”
The project has two aims: One is to evaluate the risks and benefits of genome sequencing in healthy and sick infants, with the goal of developing evidence to support guidelines for use of this technology in newborn screening or care. The second objective is to study parents’ thoughts and feelings about genetic testing, as well … Continued
Gaining information by getting your DNA sequenced on what diseases you have risks for and can take preventative measures based on this information
“We are moving to a world where the technology will get so good and the cost will get so low that it will be very appealing to apply sequencing to not only sick people but well people,” says geneticist Robert C. Green.
“Simply putting together all the pieces to design these complicated research projects is an ambitious undertaking. But it is essential that we find ways to rigorously measure the clinical utility of new technologies so that we can apply them responsibly, and that is the focus of the BabySeq Project, and of the other NSIGHT projects.”
In-vitro fertilization, above, that uses DNA from two mothers to prevent some serious diseases has been approved in Britain, and Dr. Robert Green, a geneticist at Brigham and Women’s Hospital, says the U.S. will be pressed to follow suit.
Forbes highlights the work of the BabySeq project by speaking with Laura Stetson, a mother who enrolled her daughter in the research program. By sequencing their daughter’s genome, doctors were able to quickly combat the daughters biodeficiency disease that was not caught during the standard heel stick screening.
Conducting whole-exome sequencing on newborn babies during the BabySeq project highlighted important findings on how it would affect parents. While some were willing to know the information that was coded in their baby’s genes, many were resistant to this idea because of public policy and possible insurance mishaps.
A family that had participated in the BabySeq project shares their experiences about getting their baby’s full genome test results back that showed a mutation in the elastin proteins (elastin helps heart muscles bend and stretch). The father of the baby states “.. I think the biggest regret would have been had something happened down … Continued
A general overview of BabySeq and its findings, including a detailed analysis of the risks and benefits of newborn sequencing for the future.
Highlighting the story of a family who participated in the BabySeq study that detected their newborn infants partial biotinidase deficiency. Shawn Fayer, the project manager of BabySeq and a licensed genetic counselor stated, ” Symptoms would likely have appeared if the child had become sick from something else, which makes it very difficult to diagnose. … Continued
Dr. Robert Green sits down to discuss the results of a participating family in the BabySeq project where a BRCA2 mutation was found in a baby boy and how the situation was approached to tell the family since this directly affected either one or both of the parents.
Green’s team plans to study whether knowing about such mutations is beneficial for the family in the long run, or results in unnecessary anxiety and tests.
The idea of newborn sequencing may have been initially inviting to parents who were expecting healthy children, but after learning of all the adverse effects that lead after, many decided to not follow through as research participants.
“An ongoing clinical trial at Brigham and Women’s Hospital and Boston Children’s Hospital, called BabySeq, is trying to untangle some basic questions about the benefits and harms of gene sequencing. Does it improve health? Does it lead to lots of excessive medical testing? Does it cause harm?”
A blog post authored by Dr. Robert Green discussing the benefits and challenges that people and health professionals are faced with when dealing with genetic testing and screening. Here, he addresses ethical issues and potential complications alongside beneficial factors that deal genome testing.
A family who participated in the BabySeq project at Brigham and Women’s is for genetic testing, as they wanted to be prepared, even if the test came back to show that their child would develop a life altering disease.
With advances in prenatal screenings in the Bay Area, studies have shown that more women are deciding to end Down syndrome pregnancies.
The principal investigators on the BabySeq project were trying to determine what information would be the most pertinent and helpful for both patients and physicians to know from whole-exome sequencing in the initial stages of the project. Their findings within the first couple of patients were quite interesting and they are excited to continue with … Continued
The big question is how to make genomic information useful to patients and medical practitioners; Genomes2People is looking for answers through the MedSeq and BabySeq projects, among others.
“For the first time ever doctors at Brigham & Women’s and Boston Children’s Hospital are sequencing the genome of newborns. This allows doctors to decode the DNA and look for the possibility of future diseases and conditions”
The BabySeq project in Boston at Brigham and Women’s Hospital, led by Dr. Robert Green, has begun collecting data to quantify the risks and benefits of DNA sequencing at birth.
Medical privacy and concert concerns are being addresses with newborn sequencing advances. It is predicted that there will be many changes to policy in the coming years.
A study published this week in Genetics in Medicine is the first to explore new parents’ attitudes toward newborn genomic testing. The findings suggest that if newborn genomic testing becomes available, there would be robust interest among new parents, regardless of their demographic background.
Doctors at Brigham and Women’s Hospital and Boston Children’s Hospital are developing a new clinical trial to look at the effects of genome sequencing in newborn babies.
“This first-of-its-kind study will accelerate the use of genomics in clinical pediatric medicine by creating and safely testing novel methods for integrating sequencing into the care of newborns. We will implement and study a futuristic goal: that genomic information examined shortly after birth can serve as a resource throughout infancy and childhood to inform clinical … Continued